Search
SOR-C13
go.drugbank.com/drugs/DB15366InvestigationalSOR-C13 is under investigation in clinical trial NCT01578564 (Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel).
Categories: Transient Receptor Potential ChannelsBlack widow spider antivenin (equine)
go.drugbank.com/drugs/DB14113ApprovedBlack widow spider (_Latrodectus mactans_) antivenin is a treatment for black widow spider bites derived from the serum of healthy horses immunized against black widow spider venom.[L12792]
Risuteganib
go.drugbank.com/drugs/DB14911InvestigationalRisuteganib is under investigation in clinical trial NCT02348918 (Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema).
Ispectamab debotansine
go.drugbank.com/drugs/DB18456InvestigationalIspectamab debotansine is an antibody drug conjugate comprised of an anti-B cell maturation (BCMA) IgG1 humanized antibody conjugated covalently to the dibenzocyclooctyne (DBCO) noncleavable linker maytansinoid
PCS-499
go.drugbank.com/drugs/DB15122InvestigationalPCS-499 is under investigation in clinical trial NCT01487109 (A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients).
SB-249553
go.drugbank.com/drugs/DB05285ExperimentalSB-249553 is a vaccine that has MAGE-3 cancer antigen and the Adjuvant SBAS-2. It is also under by GlaxoSmithKline to treat melanoma and lung cancer.
Prednisolone sodium metazoate
go.drugbank.com/drugs/DB05340InvestigationalReleasing the drug directly into the colon reduces the potential for significant side effects often experienced with steroid drugs. Colal-Pred is being studied for use in ulcerative colitis. … ATL-2502(Colal-Pred) is an old drug (prednisolone metasulphobenzoate, a steroid) with a new delivery system that releases the medication only in the colon.
APL-9
go.drugbank.com/drugs/DB16460InvestigationalAPL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation. … It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life.
Formebolone
go.drugbank.com/drugs/DB01569IllicitInvestigationalIt is on the list of substances prohibited by the Word Anti-Doping Agency, and is regularly screened for in athletes. … It has been used experimentally in the treatment of growth retardation, and has been noted to increase bone mass.
V24343
go.drugbank.com/drugs/DB05201InvestigationalThe anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.